Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) Short Interest Update

Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) was the recipient of a significant increase in short interest during the month of January. As of January 15th, there was short interest totalling 134,600 shares, an increase of 102.7% from the December 31st total of 66,400 shares. Based on an average daily trading volume, of 3,450,000 shares, the short-interest ratio is currently 0.0 days. Approximately 2.2% of the company’s stock are sold short.

Cyclacel Pharmaceuticals Price Performance

Shares of NASDAQ CYCC traded up $0.01 during trading on Wednesday, hitting $0.37. The stock had a trading volume of 48,491 shares, compared to its average volume of 7,043,026. Cyclacel Pharmaceuticals has a 12 month low of $0.31 and a 12 month high of $4.00. The company has a market capitalization of $2.30 million, a PE ratio of -0.04 and a beta of 0.35. The firm has a fifty day moving average of $0.37 and a two-hundred day moving average of $0.83.

Cyclacel Pharmaceuticals (NASDAQ:CYCC) last posted its quarterly earnings results on Tuesday, November 12th. The biotechnology company reported ($0.18) earnings per share for the quarter, beating the consensus estimate of ($0.54) by $0.36. The company had revenue of $0.01 million during the quarter, compared to analyst estimates of $0.01 million. Cyclacel Pharmaceuticals had a negative net margin of 18,150.00% and a negative return on equity of 1,901.11%.

Wall Street Analysts Forecast Growth

Several analysts have recently issued reports on the stock. StockNews.com assumed coverage on shares of Cyclacel Pharmaceuticals in a research note on Sunday. They issued a “sell” rating for the company. Roth Capital lowered shares of Cyclacel Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, October 23rd.

Cyclacel Pharmaceuticals Company Profile

Cyclacel Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases in the United States, the United Kingdom, and internationally. The company's lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors and hematological malignancies, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced solid tumors and hematological malignancies.